Free Trial Information
BioCentury | Feb 8, 2016
Financial News

Pacgen completes private placement of units

Pacgen Life Science Corp. (TSX-V:PBS), Vancouver, B.C. Business: Infectious, Pulmonary, Supply/Service Date completed: 2016-02-03 Type: Private placement of units Raised: C$318,000 ($226,702) Units: 5.3 million Price: C$0.06 (unit) Shares after offering: 52.5 million Investor: Company...
Read More
BioCentury | Jan 25, 2016
Financial News

Pacgen proposes private placement of units

Pacgen Life Science Corp. (TSX-V:PBS), Vancouver, B.C. Business: Infectious, Pulmonary, Supply/Service Date announced: 2016-01-19 Type: Private placement of units To be raised: C$318,000 ($219,134) Units: 5.3 million Price: C$0.06 (unit) Shares outstanding prior: 47.2 million...
Read More
BioCentury | Oct 30, 2014
Distillery Therapeutics

Indication: Inflammation

...and in Phase II testing to prevent delayed graft function (DGF) in kidney transplant recipients. Pacgen...
Read More
BioCentury | Mar 31, 2014
Company News

Pacgen, General Biologicals Corp. deal

...The companies closed a deal under which Pacgen granted General Biologicals exclusive, worldwide rights to develop...
...a preliminary deal in January. The deal excludes transitional skin-mucous membrane areas of the mouth. Pacgen...
...receive $250,000 up front and minimum annual royalties of $50,000 independent from sales or development. Pacgen...
Read More
BioCentury | Feb 3, 2014
Company News

Pacgen, General Biologicals deal

...Pacgen will receive an upfront payment and minimum annual royalties independent from sales or development. Pacgen...
...and Pacgen shareholders. Pacgen declined to disclose details, and General Biologicals could not be reached. Pacgen...
...saliva that completed Phase IIb testing (see BioCentury, March 28, 2005 & Feb. 6, 2012). Pacgen...
Read More
BioCentury | May 20, 2013
Company News

Pacgen management update

Pacgen Life Science Corp. (TSX-V:PBS), Vancouver, B.C. Business: Infectious, Pulmonary Transitioned: Chairman Chung-Yu Wang to interim CEO; he replaces Ming Liu, who stepped down and remains a director WIR Staff Infectious Pulmonary...
Read More
BioCentury | Mar 12, 2012
Company News

Pacgen management update

Pacgen Biopharmaceuticals Corp. (TSX-V:PGA), Vancouver, B.C. Business: Infectious, Inflammation, Pulmonary Hired: Peter Sheu as COO WIR Staff Infectious Inflammation Pulmonary...
Read More
BioCentury | Feb 6, 2012
Company News

Demegen, Pacgen deal

...The companies added vaginal, dermatological and ophthalmic indications to a March 2005 deal granting Pacgen worldwide...
...amendment. Details were not disclosed (see BioCentury, March 28, 2005). Demegen Inc. , Pittsburgh, Pa. Pacgen Biopharmaceuticals Corp....
Read More
BioCentury | Feb 6, 2012
Financial News

Pacgen completes private placement

Pacgen Biopharmaceuticals Corp. (TSX-V:PGA), Vancouver, B.C. Business: Infectious, Inflammation, Neurology Date completed: 1/25/12 Type: Private placement Raised: C$300,000 ($298,500) Shares: 5.4 million Price: C$0.06 Shares after offering: 47.2 million Investor: CurieMed WIR Staff Infectious Inflammation...
Read More
BioCentury | Nov 7, 2011
Company News

Pacgen management update

Pacgen Biopharmaceuticals Corp. (TSX-V:PGA), Vancouver, B.C. Business: Infectious, Inflammation, Neurology Hired: Ming Liu as CEO and a director, formerly CEO of eGene Inc. , which Qiagen N.V. acquired; he succeeds Yiu Lee, who will remain a...
Read More
Items per page:
1 - 10 of 24
BioCentury | Feb 8, 2016
Financial News

Pacgen completes private placement of units

Pacgen Life Science Corp. (TSX-V:PBS), Vancouver, B.C. Business: Infectious, Pulmonary, Supply/Service Date completed: 2016-02-03 Type: Private placement of units Raised: C$318,000 ($226,702) Units: 5.3 million Price: C$0.06 (unit) Shares after offering: 52.5 million Investor: Company...
Read More
BioCentury | Jan 25, 2016
Financial News

Pacgen proposes private placement of units

Pacgen Life Science Corp. (TSX-V:PBS), Vancouver, B.C. Business: Infectious, Pulmonary, Supply/Service Date announced: 2016-01-19 Type: Private placement of units To be raised: C$318,000 ($219,134) Units: 5.3 million Price: C$0.06 (unit) Shares outstanding prior: 47.2 million...
Read More
BioCentury | Oct 30, 2014
Distillery Therapeutics

Indication: Inflammation

...and in Phase II testing to prevent delayed graft function (DGF) in kidney transplant recipients. Pacgen...
Read More
BioCentury | Mar 31, 2014
Company News

Pacgen, General Biologicals Corp. deal

...The companies closed a deal under which Pacgen granted General Biologicals exclusive, worldwide rights to develop...
...a preliminary deal in January. The deal excludes transitional skin-mucous membrane areas of the mouth. Pacgen...
...receive $250,000 up front and minimum annual royalties of $50,000 independent from sales or development. Pacgen...
Read More
BioCentury | Feb 3, 2014
Company News

Pacgen, General Biologicals deal

...Pacgen will receive an upfront payment and minimum annual royalties independent from sales or development. Pacgen...
...and Pacgen shareholders. Pacgen declined to disclose details, and General Biologicals could not be reached. Pacgen...
...saliva that completed Phase IIb testing (see BioCentury, March 28, 2005 & Feb. 6, 2012). Pacgen...
Read More
BioCentury | May 20, 2013
Company News

Pacgen management update

Pacgen Life Science Corp. (TSX-V:PBS), Vancouver, B.C. Business: Infectious, Pulmonary Transitioned: Chairman Chung-Yu Wang to interim CEO; he replaces Ming Liu, who stepped down and remains a director WIR Staff Infectious Pulmonary...
Read More
BioCentury | Mar 12, 2012
Company News

Pacgen management update

Pacgen Biopharmaceuticals Corp. (TSX-V:PGA), Vancouver, B.C. Business: Infectious, Inflammation, Pulmonary Hired: Peter Sheu as COO WIR Staff Infectious Inflammation Pulmonary...
Read More
BioCentury | Feb 6, 2012
Company News

Demegen, Pacgen deal

...The companies added vaginal, dermatological and ophthalmic indications to a March 2005 deal granting Pacgen worldwide...
...amendment. Details were not disclosed (see BioCentury, March 28, 2005). Demegen Inc. , Pittsburgh, Pa. Pacgen Biopharmaceuticals Corp....
Read More
BioCentury | Feb 6, 2012
Financial News

Pacgen completes private placement

Pacgen Biopharmaceuticals Corp. (TSX-V:PGA), Vancouver, B.C. Business: Infectious, Inflammation, Neurology Date completed: 1/25/12 Type: Private placement Raised: C$300,000 ($298,500) Shares: 5.4 million Price: C$0.06 Shares after offering: 47.2 million Investor: CurieMed WIR Staff Infectious Inflammation...
Read More
BioCentury | Nov 7, 2011
Company News

Pacgen management update

Pacgen Biopharmaceuticals Corp. (TSX-V:PGA), Vancouver, B.C. Business: Infectious, Inflammation, Neurology Hired: Ming Liu as CEO and a director, formerly CEO of eGene Inc. , which Qiagen N.V. acquired; he succeeds Yiu Lee, who will remain a...
Read More
Items per page:
1 - 10 of 24